Table 1.
Characteristics of neoantigens targeted by identified TCRs
| Peptide name | Gene name Ensembl transcript ID | Peptide sequence | HLA restriction | Predicted affinity (nM), rank (%) | Experimental IC50 (nM) | MS FDR (%) | Reads exome PBMCs (Ref:Alt) | Reads exome MInt (Ref:Alt) | Reads exome MLung (Ref:Alt) |
| SYTL4S363F | SYTL4; ENST00000263033 | GRIAFFLKY | B27:05 | 18.43; 0.6 | 214.7±1.8 | 1 | 54:0 | 32:10 | 71:20 |
| SYTL4WT | GRIAFSLKY | 30.62; 0.12 | 97.32±2.1 | ||||||
| KIF2CP13L | KIF2C; ENST00000372224 | RLFLGLAIK | A03:01 | 21.6; 0.09 | 237.4±2.0 | 75:0 | 75:18 | 177:21 | |
| KIF2CWT | RLFPGLAIK | 12.10; 0.03 | 146.2±1.1 | ||||||
| NCAPG2P333L | NCAPG2; ENST00000409339 | KLILWRGLK | A03:01 | 32.6; 0.15 | 202.9±1.03 | 1 | 126:0 | 146:27 | 54:0 |
| NCAPG2WT | KPILWRGLK | 6946.48; 6.50 | 4,488.7±10.4 |
Alt, alternative read; FDR, false discovery rate; HLA, human leukocyte antigen; IC50, half maximal inhibitory concentration; MInt, intestinal metastasis; MLung, lung metastasis; PBMC, peripheral blood mononuclear cell; Ref, reference read; TCR, T-cell receptor.